Cargando...
A prospective, iterative, adaptive trial of carfilzomib-based desensitization
Proteasome inhibitor–based strategies hold promise in transplant but have yielded varying results. Carfilzomib, a second-generation proteasome inhibitor, may possess advantages over bortezomib, the first-generation proteasome inhibitors. The purpose of this study was to evaluate the safety, toxicity...
Gardado en:
| Publicado en: | Am J Transplant |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7872208/ https://ncbi.nlm.nih.gov/pubmed/31550069 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.15613 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|